🟢 BioCryst Pharmaceuticals is trading 5% up today after guidance rose to $690 million–$715 million

BioCryst Pharmaceuticals is trading $10.32 (+4.88%) after management raised 2026 total revenue guidance.

• The move extends the 4.90% gain recorded on August 10, 2026.
• August 5 second-quarter revenue reached $218.3 million, exceeding expectations; guidance increased to $690 million–$715 million, primarily reflecting a navenibart licensing payment.
• No newer company-specific announcement was identified on August 11, 2026; earnings and guidance remain the clearest explanation.